上海醫藥(02607.HK)子公司艾司唑侖片通過仿製藥一致性評價 2021-05-20T09:18:07-04:00May 20th, 2021| share this article! 【財華社訊】上海醫藥(02607.HK)公布,公司控股子公司山東信誼製藥有限公司收到國家藥品監督管理局頒發的關於艾司唑侖片的《藥品補充申請批准通知書》(通知書編號:2021B01316),該藥品通過仿製藥質量和療效一致性評價。艾司唑侖片主要用於抗焦慮、失眠或緊張、恐懼及抗癲癇和抗驚厥。 Read More share this article! Related Posts China’s BYD, Neta eye growth in Indonesia with new EV investments May 3rd, 2024 Collapsed US lender SVB Financial to sell venture capital business May 3rd, 2024 [Updated] Vietnamese edtech startup Prep closes Series A round led by Cercano, Northstar May 3rd, 2024 South Korea’s Naver yet to take a call on future of Japanese LY Corp stake May 3rd, 2024